Holen Sie sich die Stockscreener-App
78.29
0.03%
-0.02
Vorhandelsmarkt:
78.70
0.41
+0.52%
Schlusskurs vom Vortag:
$78.31
Offen:
$78.21
24-Stunden-Volumen:
205.43K
Relative Volume:
0.49
Marktkapitalisierung:
$1.78B
Einnahmen:
$883.37M
Nettoeinkommen (Verlust:
$71.37M
KGV:
23.36
EPS:
3.3516
Netto-Cashflow:
$150.90M
1W Leistung:
-1.48%
1M Leistung:
+11.07%
6M Leistung:
-11.78%
1J Leistung:
+13.93%
1-Tages-Spanne:
$77.60
$78.91
1-Wochen-Bereich:
$77.60
$82.08
52-Wochen-Spanne:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
78.29 | 1.78B | 883.37M | 71.37M | 150.90M | 3.3516 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals rolls out generic carbamazepine extended-release capsules - MSN
ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules - Intellectia AI
ANI Pharmaceuticals launches generic carbamazepine capsules By Investing.com - Investing.com India
Ani Pharmaceuticals’ Cook sells $38k in stock - Investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares - MarketBeat
Ani Pharmaceuticals’ Cook sells $38k in stock By Investing.com - Investing.com South Africa
ANI Pharmaceuticals (ANIP) SVP Meredith Cook sells 500 shares - Stock Titan
ANI Pharmaceuticals launches generic carbamazepine capsules - Investing.com
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules - Bitget
ANI Pharma targets $65M U.S. market with new Carbatrol generic - Stock Titan
Is ANI Pharmaceuticals Inc still a buy after recent gainsGDP Growth & Low Risk High Win Rate Picks - baoquankhu1.vn
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - TradingView — Track All Markets
Does ANI Pharmaceuticals' (ANIP) New Cardiovascular Generic Deepen Its Niche Strategy Or Stretch It? - Yahoo Finance
ANI Pharmaceuticals Expands Limited Competition Portfolio With New Cardiovascular Generic - Sahm
ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth - Seeking Alpha
ANIP Stock Price, Quote & Chart | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
Record 2025 growth at ANI Pharmaceuticals (ANIP) and key 2026 proxy votes - Stock Titan
Zacks.com featured highlights include Intuit, ANI Pharmaceuticals and Gaming and Leisure Properties - Yahoo Finance
Fed Watch: Can ANI Pharmaceuticals Inc lead its sector in growthWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet - Sahm
Did ILUVIEN’s NEW DAY Trial Publication Just Reframe ANI Pharmaceuticals' (ANIP) Retinal Franchise Narrative? - Sahm
ANI Pharmaceuticals launches generic isosorbide mononitrate tablets By Investing.com - Investing.com India
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada
Ani Pharmaceuticals announces FDA approval and launch of isosorbide mononitrate tablet - marketscreener.com
Ani Pharmaceuticals Announces FDA Approval And Launch Of Isosorbide Mononitrate Tablet - TradingView — Track All Markets
ANI Pharmaceuticals launches generic isosorbide mononitrate tablets - Investing.com
Does ANI Pharmaceuticals Inc stock have upside surprise potentialMarket Growth Report & Short-Term Trading Alerts - baoquankhu1.vn
ANI Pharmaceuticals, Inc. Files Form 8-K Announcing Auditor Change – April 2026 SEC Filing Details - Minichart
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology - Sahm
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Auditor switch at ANI Pharmaceuticals (NASDAQ: ANIP) from EisnerAmper to EY - Stock Titan
ANI Pharmaceuticals (NASDAQ:ANIP) Price Gap Sparks Nasdaq Futures Focus - Kalkine Media
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap UpHere's Why - MarketBeat
Here's the Reason ANI Pharmaceuticals (ANIP) Shows Powerful Momentum - Bitget
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock - Yahoo Finance
ANI Pharmaceuticals Publishes NEW DAY Clinical Trial Results for ILUVIEN in Ophthalmology - National Today
ANIP Technical Analysis & Stock Price Forecast - Intellectia AI
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Aberdeen Group plc - MarketBeat
Diabetic macular edema study on ILUVIEN is now in Ophthalmology - Stock Titan
ANI Pharmaceuticals Inc (ANIP) Trading 3.7% Higher on Apr 6 - GuruFocus
Travel Stocks: Will ANI Pharmaceuticals Inc stock go up in YEAR2026 Big Picture & Real-Time Stock Entry Alerts - baoquankhu1.vn
ANI Pharmaceuticals: Worthy Of A Position - Seeking Alpha
A Look At ANI Pharmaceuticals (ANIP) Valuation After Mixed Short Term Share Price Moves - Sahm
Why ANI Pharmaceuticals (ANIP) Stands Out as a Leading Long-Term Growth Stock - Bitget
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term - Yahoo Finance
ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance UK
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - TradingView — Track All Markets
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset - TradingView
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease - Yahoo Finance
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView — Track All Markets
Volume Recap: Can ANI Pharmaceuticals Inc beat the S P 5002026 Spike Watch & Consistent Return Investment Signals - baoquankhu1.vn
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):